Patents (4 active)

  • Schrier WH, Schoengold RJ, Jaseph CL, Ruggeri F. US Patent #6,008,059. “Device and methods for separating cellular components of blood from liquid portion of blood.” Issued: December 28, 1999.
  • Schrier WH, Jaseph CL, Schoengold RJ, Ruggeri F. US Patent #6,069,014. “Device and methods for separating cellular components of blood from liquid portion of blood.” Issued: May 30, 2000.
  • Schrier WH, Jaseph CL, Schoengold RJ, Ruggeri F. US Patent #6,197,598 B1. “Device and methods for separating cellular components of blood from liquid portion of blood.” Issued: March 6, 2001.
  • Schrier WH, Silzel J, Matusewicz RS, Schoengold RJ. U.S. Patent # 6,850,633“Devices and methods for reading and interpreting guaiac-based occult blood tests.” Issued February 1, 2005.

Publications

  • Schoengold RJ, Pagano JF, Actor P. Semi-automated technique for rubella hemagglutination-inhibition test. Bact Proc 1969 (Abstract) V333.
  • Gold JA, McKee J, Schoengold RJ, Graham K. Rubella vaccine field trials in Symposium on Rubella, Mt. Zion Hospital, San Francisco, California, October 1, 1969.
  • Corretjer J, Farquhar JD, Oliver-Gonzalez J, Schoengold RJ, Ferlauto RJ. Study with rubella vaccine, Cendehill strain, in family and school settings. JAMA 1969;210(2):342.
  • Farquhar JD, Plotkin SA, Schoengold RJ. Cendehill strain of rubella vaccine: clinical evaluation. J Pediat 1969;75(3):412-417.
  • Farquhar JD, Plotkin SA, Schoengold RJ. Results of a two year study with Cendehill rubella vaccine. International Symposium on Rubella Vaccines (London), Symposium Series in Immunobiological Standardization, V II, Karger, Basel, New York 1969; pages 331-336.
  • Deforest A, Fisher DE, Schoengold RJ. Persistence of antibody in adult women following rubella vaccination, Cendehill strain. Clin Res 1970;18(4):688.
  • Berry LJ, Smyth DS, Colwell LS, Schoengold RJ, Actor P., Comparison of the effects of synthetic polyribonucleotide with the effects of endotoxin on selected host response. Infect Immun 1971;3(3):444-448.
  • Pierce NF, Schoengold RJ, Actor P. Failure of vibriocidal antibody to protect against experimental canine cholera. Infect Immun 1974;6(4):554-556.
  • Schoengold, RJ. Optimizing the relationship between quality control and manufacturing. (Presentation) Santa Clara Chapter, American Society of Quality Control, July 18, 1978.
  • Schoengold RJ, Evenson E. The production and standardization of laboratory reagents. WHO Workshop, Shanghai Institute of Biological Products, People’s Republic of China, September 1982 (Invited guest of the Ministry of Health, People’s Republic of China).
  • Schrier WH, Schoengold RJ, Norell J, Jaseph C, Okin Doe J, Lasarow-Tozzi B, Chandler H. Development of FlexSure™ HP test–an immunochromatographic method to detect antibodies against Helicobacter pylori. Clin Chem (Abstract and Poster) 1994;40(6), New Orleans.
  • Schrier WH, Jaseph C, Schoengold RJ. FlexSure™ HP Whole Blood–A rapid method to detect antibodies against Helicobacter pylori. Gut (Abstract and Poster) 1995;37(1), Edinburgh, Scotland.
  • Schrier WH, Schoengold RJ, Baker JT, Norell JL, Jaseph CL, Okin Y, Doe J, Chandler H. Development of FlexSure® HP–an immunochromatographic method to detect antibodies against Helicobacter pylori. Clin Chem 1998;44(2):293-298.
  • Schoengold RJ. Promoting compliance by general physicians for screening with fecal occult blood tests. (Presentation) The Israel Society of Preventive Oncology, Herziliya, Israel, April 1999.
  • Schoengold RJ. Preparation, development and interpretation of FOBTs. (Presentation) OMED Meeting, Rome, Italy, November 1999.
  • Schoengold RJ, Fleisher M. Occult Blood. In: Point-of-care testing: performance improvement and evidence based outcomes (Nichols JH, ed.). New York: Marcel Dekker, 2002.
  • Schoengold, R Internal IVD Audit: Readiness for an FDA Inspection. Regulatory Focus 2011;16(5):9-11.
  • Schoengold, R, Advances in Colorectal Cancer Screening. (Presentation) Bio2 Device Group Lecture, Sunnyvale, California, January 7, 2014.